Investment in associates (Details Narrative) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
Mar. 31, 2024 |
|
| IfrsStatementLineItems [Line Items] | |||
| Loss of disposal | $ 215 | ||
| Vax Biotech Sdn Bhd [member] | |||
| IfrsStatementLineItems [Line Items] | |||
| Total consideration | 0.47 | ||
| Loss of disposal | $ 677 | ||
| Effective equity interest | 30.00% | ||
| Cilo Cybin Pharmaceutical [Member] | |||
| IfrsStatementLineItems [Line Items] | |||
| Effective equity interest | 9.98% | ||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Total for all business combinations [member]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The gain on the disposal of investments. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|